https://cybin.com/
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally-recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues.

https://cybin.com/cyb003/
CYB003 is a proprietary deuterated molecule related to psilocybin, which is part of a family of molecules called indolamines that includes more common neurotransmitters like serotonin. CYB003 is a new chemical entity (NCE) and has been granted FDA Breakthrough Therapy Designation for the adjunctive treatment of Major Depressive Disorder (MDD).

https://finance.yahoo.com/quote/CYBN/
1.1500. -9.45%. Find the latest Cybin Inc. (CYBN) stock quote, history, news and other vital information to help you with your stock trading and investing.

https://www.drugs.com/clinical_trials/cybin-receives-fda-breakthrough-therapy-designation-novel-psychedelic-molecule-cyb003-announces-21392.html
Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business

https://www.msn.com/en-us/health/other/a-breakthrough-moment-in-mental-health-cybin-s-milestone-in-fighting-depression/ar-BB1kaybW
On March 13, 2024, Cybin Inc. further showcased its leadership and innovative spirit in the mental health space with the announcement of an oversubscribed private placement of US$150 million. This

https://finance.yahoo.com/news/cybin-announces-fda-clearance-initiate-123000262.html
TORONTO, January 23, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by

https://finance.yahoo.com/news/cybin-receives-fda-breakthrough-therapy-100000465.html
TORONTO, March 13, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by

https://ir.cybin.com/overview/default.aspx
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin's goal of revolutionizing mental healthcare is supported by a network of world-class

https://www.businesswire.com/news/home/20230524005312/en/Cybin-Initiates-First-in-Human-Dosing-of-CYB004-in-Phase-1-Clinical-Trial
The Phase 1 trial is a three-part study evaluating the safety, pharmacokinetics, and pharmacodynamics of escalating doses of DMT and CYB004 in healthy volunteers. The three-part study design was

https://www.businesswire.com/news/home/20230921411645/en/Cybin-Completes-Enrollment-in-Phase-2-Study-of-CYB003-in-Major-Depressive-Disorder/
The CYB003 program is supported by a recently granted U.S. patent covering composition of matter claims until 2041. Further, the Company anticipates potential Breakthrough Therapy designation

https://www.prnewswire.com/news-releases/cybin-announces-unprecedented-positive-interim-phase-2-data-for-cyb003-in-major-depressive-disorder-meeting-primary-efficacy-endpoint-with-rapid-and-significant-improvements-in-depression-symptoms-after-single-dose---full-topline--301972342.html
This news release constitutes a "designated news release" for the purposes of Cybin's prospectus supplements each dated August 23, 2023, to its short form base shelf prospectus dated August 17, 2023.

https://ca.finance.yahoo.com/quote/CYBN.NE/
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase. TORONTO, May 14, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale

https://cybin.com/our-team/
Prior to joining Cybin, George was Chief Executive Officer and director of Small Pharma, which he initially joined in 2015 as a director. George has over 15 years of experience in investment banking and international capital markets having worked at a number of global financial institutions including Goldman Sachs, Credit Suisse, Nomura, Lehman Brothers and CIBC.

https://www.businesswire.com/news/home/20240108181308/en/Cybin-Announces-Positive-Topline-Data-from-Phase-1-Studies-of-Proprietary-Deuterated-DMT-Molecules-CYB004-and-SPL028
Cybin's goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery

https://finance.yahoo.com/news/cybin-provides-corporate-highlights-upcoming-123200530.html
TORONTO, May 06, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by

https://www.businesswire.com/news/home/20231116986353/en/Cybin-to-Release-Phase-2-Topline-Safety-and-Efficacy-Data-for-CYB003-in-Major-Depressive-Disorder-and-Host-RD-Briefing-on-November-30-2023
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment

https://cybin.com/development-pipeline/
CYB003 is a proprietary molecule derived from psilocybin, which is part of a family of molecules called indolamines that includes more common neurotransmitters like serotonin. Psilocybin is dephosphorylated to form its metabolite, psilocin, which can cross the blood-brain-barrier. Given its structural similarity to serotonin, psilocybin can

https://www.cnn.com/markets/stocks/CYBN
Cybin, Inc. is a clinical-stage biopharmaceutical company. The company's mission is to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and

https://stockanalysis.com/stocks/cybn/
About CYBN. Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating

https://cybin.com/cyb004/
Cybin is developing CYB004 for the treatment of Anxiety Disorders, specifically Generalized Anxiety Disorder (GAD). CYB004, a deuterated dimethyltryptamine (dDMT), has been shown to exert its psychedelic effects by activating the 5-HT2A receptor. In its regular form, DMT is an unstable molecule rapidly metabolized in the body, which

https://finance.yahoo.com/news/cybin-announces-positive-end-phase-113000456.html
TORONTO, March 14, 2024--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by

https://www.crunchbase.com/organization/cybin-corp
Contact Email info@cybin.com. Phone Number 908-764-8385. Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin's goal of revolutionizing

https://cybin.com/partnerships/
Cybin has formed a collaboration with the University of Washington and is supporting a trial that aims to treat symptoms of depression, anxiety, burnout and post-traumatic stress among frontline doctors, nurses and healthcare professionals through psychedelic therapeutics. The trial is led by Dr. Anthony Back and hosted in Seattle, a city hard